Researchers develop new drugs for treating polycystic hepatorenal diseases
12 May 2020

The drugs are based on the structure of ursodeoxycholic acid (UDCA), a bile acid present in the body at a low concentration and which has protective properties for the liver. Its administration is recommended for treating specific liver diseases. The researchers studied the structure and properties of this molecule to design and synthesise a family of chemical derivatives geared toward inhibiting a key protein responsible for encouraging the growth of hepatorenal cysts. The results have shown that these new drugs are capable of blocking the growth of hepatic and renal cysts in an animal model of this disease.

The promising therapeutic effects of these new drugs have sparked great interest in the international scientific community, and the work was selected for oral presentation at the International Congress of the EASL, the European Association for the Study of the Liver, held in Vienna. It has also been published recently in the international journal Hepatology.


Provided by University of the Basque Country

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.